Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Mylan Must Pay Ipsen $24 Million on Generics, Paris Court Says

May 17 (Bloomberg) -- Mylan Inc., a U.S. maker of generic medicines, was ordered by a Paris court to pay French drugmaker Ipsen SA 17 million euros ($24 million) for presenting a pill to pharmacists as a substitute for an Ipsen product.

Mylan marketed its drug, Vitalogink, as the “generic drug” of Ipsen’s memory-aid pill Tanakan, rather than as its “therapeutic equivalent,” the Paris court of appeals said in its April 28 decision, reversing a 2008 commercial court ruling.

Mylan’s marketing was “meant to lead prescribers, pharmacists and patients into error, to reap unwarranted profits from the ensuing confusion, at Ipsen Pharma’s expense,” the appeals court said.

Canonsburg, Pennsylvania-based Mylan will appeal the decision to France’s highest appeals court, the company said in a statement.

To contact the reporter on this story: Heather Smith in Paris at hsmith26@bloomberg.net

To contact the editor responsible for this story: Anthony Aarons at aaarons@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.